<div id="readability-page-1"><div><p>Natera, Inc. announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO GI) earlier this year. CALGB (Alliance)/SWOG 80702 assessed the predictive value of postoperative personalized circulating tumor DNA (ctDNA) in patients with stage III colorectal cancer (CRC).</p><p>The pre-specified post-hoc analysis included 940 patients with available post-surgical plasma samples, who were randomized to receive FOLFOX +/- celecoxib, a non-steroidal anti-inflammatory drug (NSAID). Key findings included: Adding celecoxib to conventional chemotherapy in Signatera-positive patients, after surgery reduced the risk of cancer recurrence and death by ~40%. Celecoxib improved disease-free survival (DFS) (adjusted HR=0.61, 95% CI 0.42-0.89; 3-year 41.0% vs.</p><p>22.6%) and overall survival (OS) (adjusted HR=0.,62, 95% CI 0.40-0.96; 5-year: 61.6% vs. 39.9%) compared to placebo in Signatera-positive patient. Celecoxib benefit in Signatera-positive Patients was independent of demographic, pathologic or molecular factors, including PIK3CA status, further defining a patient population who may benefit from the addition to adjvant treatment.</p><p>Celecoxib improved DFS of Signatera-positive patients for both PIK3CA wild-type (adjusted HR=0.64, 95% CI 0. 42-0.98) and PIK3CA altered (adjusted HR=0.19, 95% CI 0.06-0.58) tumors.</p></div></div>

NTRA

<p>Natera, Inc. 宣佈在《JAMA Oncology》上發表了 CALGB/SWOG 80702 研究的結果，顯示在 Signatera 陽性的結直腸癌患者中，添加塞來昔布到化療中可將復發和死亡風險降低約 40%。塞來昔布改善了無病生存期和總體生存期，與人口統計學或分子因素（包括 PIK3CA 狀態）無關</p>

Natera 公司宣佈在結直腸癌的隨機 III 期 CALGB/SWOG 80702 研究中發表 Signatera 分析結果